VectorY Therapeutics has secured €129m ($138m) in a Series A funding round to progress the development of its vectorised antibody programmes in neurodegenerative diseases. EQT Life Sciences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback